Can domestic formulations shield Indian pharma from US pricing pressure in Q3?

January 16, 2026

Indian drugmakers anticipate a mixed third quarter. Domestic sales and new specialty drugs will drive growth. US generics will see new product boosts. Contract services and APIs are set for moderate gains. Sun Pharma and Lupin are poised for leadership. Cipla and Dr Reddy’s face softer US sales. Divi’s Laboratories expects strong custom synthesis growth.

More To Explore

FIIs sold about Rs 11,000 crore worth Indian stocks in 2 days of US-Iran war

Foreign investors sold nearly Rs 11,000 crore in two March sessions amid escalating West Asia tensions, surging crude prices and currency volatility. DIIs offered support,

March 4, 2026

Sebi revises reporting norms for AIFs, introduces annual activity report

Sebi has revised the reporting framework for Alternative Investment Funds, replacing detailed quarterly submissions with a comprehensive annual report, reducing compliance burden, improving ease of

March 4, 2026

Advertiser Disclosure

Great-investor.com helps users across the globe to find out The latest news, Guides, and Info about finance and investments. Furthermore, our content and research teams do not participate in any advertising planning nor are they permitted access to advertising campaign data.

Disclaimer

It is our organization’s primary mission to provide reviews, commentary, and analysis that are unbiased and objective. While great-investor.com has some data verified by industry participants, it can vary from time to time. Operating as an online business, this site may be compensated through third party advertisers. Our receipt of such compensation shall not be construed as an endorsement or recommendation by great-investor.com, nor shall it bias our reviews, analysis, and opinions. Please see our General Disclaimers for more information.

The information on this website does not constitute investment advice or a recommendation or a solicitation to engage in any investment activity. This website and its content are not intended for residents of the UAE, US, Canada, Australia, UK, Russia, North Korea, China, Japan, Hong Kong, Singapore and Iran.

Top10 International FZ LLE | 17th Floor, Creative Tower | 4422 | Fujairah | TRN: 100608946800003